In a recent study, Osimertinib plus intermittent Selumetinib (MEK1/MEK2 inhibitor) demonstrated preliminary antitumor activity in patients with EGFR-mutated NSCLC who progressed to prior EGFR TKI. This evidence concerns the gene MAP2K2 and non-small cell lung carcinoma.